Annual EBITDA
-$57.38 M
+$6.98 M+10.85%
30 September 2023
Summary:
Outlook Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$57.38 million, with the most recent change of +$6.98 million (+10.85%) on 30 September 2023. During the last 3 years, it has fallen by -$5.41 million (-10.42%). OTLK annual EBITDA is now -398.32% below its all-time high of -$11.51 million, reached on 30 September 2014.OTLK EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$44.44 M
+$63.35 M+334.97%
30 June 2024
Summary:
Outlook Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently $44.44 million, with the most recent change of +$63.35 million (+334.97%) on 30 June 2024. Over the past year, it has increased by +$58.39 million (+418.53%). OTLK quarterly EBITDA is now at all-time high.OTLK Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$1.28 M
+$65.10 M+102.01%
30 June 2024
Summary:
Outlook Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently $1.28 million, with the most recent change of +$65.10 million (+102.01%) on 30 June 2024. Over the past year, it has increased by +$58.40 million (+102.24%). OTLK TTM EBITDA is now at all-time high.OTLK TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
OTLK EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +418.5% | +102.2% |
| 3 y3 years | -10.4% | +439.6% | +102.5% |
| 5 y5 years | -84.5% | +482.1% | +104.1% |
OTLK EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -10.4% | +10.8% | at high | +315.1% | at high | +101.9% |
| 5 y | 5 years | -84.5% | +10.8% | at high | +315.1% | at high | +101.9% |
| alltime | all time | -398.3% | +10.8% | at high | +307.4% | at high | +101.9% |
Outlook Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | $44.44 M(-335.0%) | $1.28 M(-102.0%) |
| Mar 2024 | - | -$18.91 M(+83.7%) | -$63.82 M(+23.4%) |
| Dec 2023 | - | -$10.29 M(-26.2%) | -$51.74 M(-9.4%) |
| Sept 2023 | -$57.38 M(-10.8%) | -$13.95 M(-32.5%) | -$57.12 M(-2.5%) |
| June 2023 | - | -$20.66 M(+202.7%) | -$58.60 M(+6.7%) |
| Mar 2023 | - | -$6.83 M(-56.5%) | -$54.90 M(-18.0%) |
| Dec 2022 | - | -$15.68 M(+1.6%) | -$66.94 M(+2.5%) |
| Sept 2022 | -$64.36 M(+23.9%) | -$15.43 M(-9.1%) | -$65.32 M(+3.7%) |
| June 2022 | - | -$16.97 M(-10.0%) | -$62.98 M(+8.8%) |
| Mar 2022 | - | -$18.86 M(+34.1%) | -$57.89 M(+11.7%) |
| Dec 2021 | - | -$14.06 M(+7.5%) | -$51.81 M(-0.3%) |
| Sept 2021 | -$51.96 M(+43.5%) | -$13.08 M(+10.0%) | -$51.96 M(+6.7%) |
| June 2021 | - | -$11.89 M(-6.9%) | -$48.70 M(+14.5%) |
| Mar 2021 | - | -$12.77 M(-10.2%) | -$42.53 M(+23.0%) |
| Dec 2020 | - | -$14.22 M(+44.7%) | -$34.59 M(-4.5%) |
| Sept 2020 | -$36.20 M(+16.4%) | -$9.82 M(+71.7%) | -$36.20 M(-4.8%) |
| June 2020 | - | -$5.72 M(+18.5%) | -$38.01 M(+6.8%) |
| Mar 2020 | - | -$4.83 M(-69.5%) | -$35.59 M(-9.1%) |
| Dec 2019 | - | -$15.83 M(+36.1%) | -$39.14 M(+25.8%) |
| Sept 2019 | -$31.11 M | -$11.63 M(+252.1%) | -$31.11 M(+2.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2019 | - | -$3.30 M(-60.6%) | -$30.24 M(-9.5%) |
| Mar 2019 | - | -$8.37 M(+7.4%) | -$33.40 M(+8.0%) |
| Dec 2018 | - | -$7.80 M(-27.6%) | -$30.92 M(+15.4%) |
| Sept 2018 | -$26.79 M(-10.8%) | -$10.77 M(+66.6%) | -$26.79 M(+40.4%) |
| June 2018 | - | -$6.46 M(+9.8%) | -$19.09 M(+22.8%) |
| Mar 2018 | - | -$5.89 M(+60.1%) | -$15.54 M(-1.5%) |
| Dec 2017 | - | -$3.68 M(+20.2%) | -$15.77 M(-47.5%) |
| Sept 2017 | -$30.03 M(-38.7%) | -$3.06 M(+5.0%) | -$30.03 M(-17.3%) |
| June 2017 | - | -$2.91 M(-52.4%) | -$36.32 M(-33.8%) |
| Mar 2017 | - | -$6.12 M(-65.9%) | -$54.84 M(+7.4%) |
| Dec 2016 | - | -$17.94 M(+91.8%) | -$51.07 M(+4.3%) |
| Sept 2016 | -$48.95 M(+9.4%) | -$9.35 M(-56.4%) | -$48.95 M(-12.6%) |
| June 2016 | - | -$21.43 M(+809.6%) | -$56.01 M(+23.9%) |
| Mar 2016 | - | -$2.36 M(-85.1%) | -$45.21 M(-20.2%) |
| Dec 2015 | - | -$15.82 M(-3.6%) | -$56.64 M(+26.6%) |
| Sept 2015 | -$44.74 M(+288.6%) | -$16.41 M(+54.4%) | -$44.74 M(+57.9%) |
| June 2015 | - | -$10.62 M(-22.9%) | -$28.33 M(+60.0%) |
| Mar 2015 | - | -$13.78 M(+251.5%) | -$17.70 M(+351.5%) |
| Dec 2014 | - | -$3.92 M | -$3.92 M |
| Sept 2014 | -$11.51 M | - | - |
FAQ
- What is Outlook Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Outlook Therapeutics?
- What is Outlook Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Outlook Therapeutics?
- What is Outlook Therapeutics quarterly EBITDA year-on-year change?
- What is Outlook Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Outlook Therapeutics?
- What is Outlook Therapeutics TTM EBITDA year-on-year change?
What is Outlook Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of OTLK is -$57.38 M
What is the all time high annual EBITDA for Outlook Therapeutics?
Outlook Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$11.51 M
What is Outlook Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of OTLK is $44.44 M
What is the all time high quarterly EBITDA for Outlook Therapeutics?
Outlook Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $44.44 M
What is Outlook Therapeutics quarterly EBITDA year-on-year change?
Over the past year, OTLK quarterly earnings before interest, taxes, depreciation & amortization has changed by +$58.39 M (+418.53%)
What is Outlook Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of OTLK is $1.28 M
What is the all time high TTM EBITDA for Outlook Therapeutics?
Outlook Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $1.28 M
What is Outlook Therapeutics TTM EBITDA year-on-year change?
Over the past year, OTLK TTM earnings before interest, taxes, depreciation & amortization has changed by +$58.40 M (+102.24%)